Equivalencies: 0 | Classes: 0 | Children: 1 | Explore

Entity

Name
NMDA receptor antagonist
Namespace
chebi
Namespace Version
20180906
Namespace URL
https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns

Appears in Networks 3

In-Edges 3

bp(GO:"GO:0035249") association a(CHEBI:"NMDA receptor antagonist") View Subject | View Object

ChEIs are believed to target cholinergic abnormalities in Alzheimer's disease, although there is evidence indicating that their therapeutic effect may be via the glutamatergic system. NMDA receptor antagonists, in contrast, are believed to target the glutamatergic system directly PubMed:16273023

bp(GO:cognition) positiveCorrelation a(CHEBI:"NMDA receptor antagonist") View Subject | View Object

There are no cures for any tauopathy. Neuroprotective agents, such as acetylcholinesterase inhibitors and NMDA antagonists, have been approved for use in the clinic, based on their ability to slow the rate of cognitive decline in patients with moderate to severe AD (reviewed in [36]) PubMed:21882945

Out-Edges 3

a(CHEBI:"NMDA receptor antagonist") association bp(GO:"GO:0035249") View Subject | View Object

ChEIs are believed to target cholinergic abnormalities in Alzheimer's disease, although there is evidence indicating that their therapeutic effect may be via the glutamatergic system. NMDA receptor antagonists, in contrast, are believed to target the glutamatergic system directly PubMed:16273023

a(CHEBI:"NMDA receptor antagonist") decreases act(a(MESH:D009474)) View Subject | View Object

With regard to the glutamatergic system, studies suggest that ChEIs may stimulate the release of glutamate from pyramidal neurons during normal neuronal activity, while NMDA receptor antagonists are believed to block the abnormal neuronal activity that results from the presence of excess glutamate in the synapse under resting conditions. Thus, ChEIs and NMDA receptor antagonists appear to have complementary effects, as the former enhance the signals received by postsynaptic neurons during normal neurotransmission, and the latter diminish the background 'noise' that is constantly being detected by those same receptors. PubMed:16273023

a(CHEBI:"NMDA receptor antagonist") positiveCorrelation bp(GO:cognition) View Subject | View Object

There are no cures for any tauopathy. Neuroprotective agents, such as acetylcholinesterase inhibitors and NMDA antagonists, have been approved for use in the clinic, based on their ability to slow the rate of cognitive decline in patients with moderate to severe AD (reviewed in [36]) PubMed:21882945

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.